Previous Article | Next Article 
Molecular and Cellular Biology, August 2000, p. 5974-5985, Vol. 20, No. 16
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Receptor Isoforms Mediate Opposing Proliferative
Effects through G
-Activated p38 or Akt Pathways
Lynda A.
Sellers,*
Forbes
Alderton,
Alan M.
Carruthers,
Marcus
Schindler, and
Patrick P. A.
Humphrey
Glaxo Institute of Applied Pharmacology,
Department of Pharmacology, University of Cambridge, Cambridge CB2
1QJ, United Kingdom
Received 19 January 2000/Returned for modification 15 March
2000/Accepted 17 May 2000
 |
ABSTRACT |
The opposing effects on proliferation mediated by G-protein-coupled
receptor isoforms differing in their COOH termini could be correlated
with the abilities of the receptors to differentially activate p38,
implicated in apoptotic events, or phosphatidylinositol 3-kinase (PI
3-K), which provides a source of survival signals. These contrasting
growth responses of the somatostatin sst2 receptor isoforms, which couple to identical G
subunit pools
(G
i3 > G
i2 >> G
0),
were both inhibited following 
sequestration. The
sst2(a) receptor-mediated ATF-2 activation and inhibition
of proliferation induced by basic fibroblast growth factor (bFGF) were
dependent on prolonged phosphorylation of p38. In contrast, cell
proliferation and the associated transient phosphorylation of Akt and
p70rsk induced by sst2(b) receptors
were blocked by the PI 3-K inhibitor LY 294002. Stimulation with bFGF
alone had no effect on the activity of either p38 or Akt but markedly
enhanced p38 phosphorylation mediated by sst2(a) receptors,
suggesting that a complex interplay exists between the transduction
cascades activated by these distinct receptor types. In addition,
although all receptors mediated a sustained activation of extracellular
signal-regulated kinases (ERK1 and ERK2), induction of the tumor
suppressor p21cip1 was detected only following
amplification of ERK and p38 phosphorylation by concomitant bFGF and
sst2(a) receptor activation. Expression of constitutively
active Akt in the presence of a p38 inhibitor enabled a proliferative
response to be detected in sst2(a) receptor-expressing cells. These findings demonstrate that the duration of activation and a
critical balance between the mitogen-activated protein kinase and PI
3-K pathways are important for controlling cell proliferation and that
the COOH termini of the sst2 receptor isoforms may
determine the selection of appropriate 
-pairings necessary for
interaction with distinct kinase cascades.
 |
INTRODUCTION |
Mitogen-activated protein (MAP)
kinases are proline-directed serine/threonine kinases that play
important roles as mediators of cellular responses to a variety of
stimuli such as growth factors, cytokines, hormones, and environmental
stresses (18, 23). MAP kinases in mammalian cells have been
classified into at least four subfamilies: extracellular
signal-regulated kinases (ERKs), stress-activated protein kinases/c-Jun
NH2-terminal kinase (SAPKs/JNK), p38 kinases, and BMK1/ERK5
(51). ERK is activated by many growth factors and cytokines
and is implicated in cell growth as well as differentiation
(32). Various stressors such as chemical agents and UV
irradiation, tumor necrosis factor, interleukin-1, CD40 ligand, and
Fas/CD95 ligand stimulate the activities of SAPKs and p38 (10,
24) which appear to play a decisive role in the control of cell
death. Thus, the SAPK pathway is critical during ceramide-induced
(49) and stress-induced (56) apoptosis as well as
in the Daxx-mediated Fas cascade (55), whereas transfection of a constitutively active mutant of MKK3/6, the physiological activator of p38, is sufficient to induce apoptosis in PC-12 cells (53). In contrast, overexpression of ERK in NIH 3T3 cells
impairs a large part of the UV-induced apoptotic response and the
inhibition of ERK below a basal threshold level triggers apoptosis
(2), suggesting that besides its well-established role in
cell cycle progression, ERK controls survival. BMK1 is a
redox-regulated kinase and phosphorylates the transcription factor
MEF2C, although its physiological role has remained unclear
(23).
Recently, considerable attention has also been focused on the role of
phosphatidylinositol 3-kinase (PI 3-K) in protecting against apoptosis
and promoting cell proliferation (21). Studies indicate that
insulin supports the survival of primary cerebellar neurons by
activation of the serine/threonine protein kinase Akt (also known as
PKB-
) (4, 14). Akt is a widely expressed kinase that is
activated by a PI 3-K-dependent mechanism (5), and it has
been shown to phosphorylate and inactivate the
Bcl-XL/Bcl-2-associated death promoter (11) as well as
caspases (48). Another downstream component of the PI
3-K pathway required for G1 cell cycle progression is p70
S6 kinase (p70rsk) (6, 37). This
kinase phosphorylates the 40S subunit of ribosomal protein S6 and is
involved in the translational control of 5'-oligopyrimidine tract
mRNAs. Thus, in addition to the two regulatory pathways mediated by
SAPKs and p38 which culminate in apoptotic processes, the ERK and PI
3-K cascades can evoke the induction of cell survival and proliferative events.
In the present study, we have examined the ability of two
G-protein-coupled receptors to differentially activate these kinase pathways in order to explain the opposing effects of the receptors on
cell proliferation. The somatostatin sst2(a) and
sst2(b) receptor splice variants differ only in length and
composition of their intracellular COOH termini and inhibit adenylate
cyclase activity with similar potency when recombinantly expressed in
Chinese hamster ovary (CHO-K1) cells (38). However, initial
findings revealed that only the sst2(b) receptor mediated
an increase in cell number while having no effect on the proliferation
induced by basic fibroblast growth factor (bFGF), which was potently
inhibited following activation of sst2(a) receptors.
Whereas the pathway linking cell surface receptors to ERKs has been
partially elucidated (51), the mechanism of activation of
p38 and SAPKs is poorly understood. This is particularly so for members
of the G-protein-coupled receptor family, which have only recently been
shown to utilize these alternative MAP kinase cascades for transduction
purposes. Activation of p38 (54) and JNK (7) has
been demonstrated following stimulation of the Gq/G11-coupled m1 and
Gi-coupled m2 muscarinic acetylcholine
receptors, and the integration of signals transduced by both these MAP
kinase family members appears to be necessary for the m1
muscarinic receptor to activate the c-jun promoter
(31). Although the expression of the c-jun
proto-oncogene is rapidly induced in response to numerous mitogens and
the resulting functional activity of c-Jun proteins appears to be
critical for cell proliferation, a role for SAPKs or p38 in controlling
cell growth through G-protein-coupled receptors has yet to be
demonstrated. Part of this study was to determine if the
sst2(a) and sst2(b) receptor isoforms can
differentially regulate these alternative MAP kinase cascades and thus
subsequently modulate transcription factor activation, cell
proliferation, and the expression of the cell cycle inhibitor
p21cip1, which has been suggested to play a
pivotal role (15) in mediating the well-established
antiproliferative effect of somatostatin (3, 35). Changes in
proliferative responses with the activation of a particular kinase
cascade including that of PI 3-K were also correlated for bFGF. In
addition, the time course of the kinase activity was determined. There
is much evidence to suggest that the duration of ERK activity is
critical for determining the proliferative outcome (32), and
in every case examined thus far, only sustained ERK activation induces
cytoplasmic-nuclear migration (12, 46). Prolonged
stimulation of ERK will therefore have very different consequences for
gene expression than will transient activation. Part of this study was
thus designed to determine if the duration of the other MAP kinase
cascades is similarly important for controlling proliferative events.
Our data suggest that prolonged p38 MAP kinase activity plays an
essential role in mediating the induction of
p21cip1 and the concomitant antiproliferative
function of the sst2(a) receptor isoform whereas
proliferation induced by the sst2(b) receptor is dependent
on Akt and a sustained ERK activity.
 |
MATERIALS AND METHODS |
Cell culture and determination of cell number.
The cDNA
encoding the rat sst2(a) or sst2(b) receptors
was subcloned into the mammalian expression vector pAlphaCA12 harboring a neomycin resistance gene as a selection marker, and stable cell lines
expressing the recombinant receptors were prepared as described previously (38). Receptor expression was assessed by binding of 125I-Tyr11-somatostatin. The estimated
Bmax values for the two clonal lines were
similar, at 2.2 ± 0.6 and 1.9 ± 0.4 pmol/mg of membrane
protein for CHOsst2(a) and CHOsst2(b) cells,
respectively (n = 3 for both data sets). Recombinant
cells were cultured in Dulbecco's modified Eagle's medium-Ham's F12
medium (1:1) containing 10% (vol/vol) fetal calf serum, 0.5 mg of G418
sulfate per ml, and 1 mM Glutamax I. To assess the effect of various
treatments on cell number, the clonal lines were grown to confluence in
complete medium on Thermanox coverslips. Multiple denuded areas (400 µm wide) were produced by a method described previously
(40). The Perspex comb was designed so that 50% of the
confluent monolayer was removed by the partial denudation process.
Repopulation of the denuded areas was investigated by placing the
coverslip into a fresh well containing drug or vehicle in medium
without serum. Cells were harvested following incubation for 24 h
by washing the coverslip in phosphate-buffered saline and adding 0.05%
(wt/vol) trypsin-0.02% (wt/vol) EDTA solution for 2 to 5 min, and the
single-cell suspension was counted using a Coulter Counter model Z1.
Results are expressed as the mean cell number (± standard error of the
mean) harvested from a single coverslip (n = 3, three
replicates per test group). Statistical analysis was carried out by
Student's t test.
Determination of phosphorylation changes.
To analyze changes
in the phosphorylation status of the MAP kinase family members, ATF-2,
p70rsk, and Akt at various stages during the
repopulation processes following partial denudation, whole-cell protein
extract was combined from four coverslips for each treatment group.
Termination of the phosphorylation events following the appropriate
investigative period was achieved by washing the clonal CHO-K1 cell
monolayers in ice-cold phosphate-buffered saline before applying sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample
buffer as previously described (40). Total-cell protein for
each of the extracts was measured by the microBCA (Pierce) method, and equivalent amounts of protein were electrophoretically resolved on 10%
polyacrylamide gels. Following electrophoretic transfer onto
nitrocellulose (pore size, 0.22 µm) using a semidry blotter, the
membrane was washed briefly in Tris-buffered saline (TBS) and saturated
overnight in TBS supplemented with 0.1% (vol/vol) Tween 20 and 5%
(wt/vol) dried milk. For detection of the phosphorylated forms of the
kinases, the nitrocellulose membrane was incubated with a 1:1,000
dilution of the antiphosphospecific antibodies (New England Biolabs,
Inc.). Antibodies recognizing the kinases independent of their
phosphorylation state (New England Biolabs, Inc.) were also used at a
1:1,000 dilution, except for those specific to ERK1 and ERK2 (Santa
Cruz Biotechnology, Inc.), which were used at a 1:2,000 dilution (1:1
mix of ERK1 and ERK2). Primary incubations were carried out for 1 h at 22°C in TBS containing 0.1% (vol/vol) Tween 20 (TBST), and the
membranes were washed five times for 10 min each in TBST. They were
then incubated for 1 h at 22°C with a 1:3,000 dilution of the
appropriate horseradish peroxidase-conjugated secondary antibody in
TBST containing 5% (wt/vol) dried milk. Excess antibody was removed by
washing as above, and immunocomplexes were visualized using enhanced
chemiluminescence detection as specified by the manufacturer (Amersham
Life Science). The Western blots shown are representative of three
independent experiments, and each panel is taken from a single immunoblot.
Induction of p21cip1 and transient
expression of active Akt and transducin.
Whole-cell protein
extracts were prepared 24 h following partial denudation and
analyzed by Western blotting using an
anti-p21cip1 antibody (Upstate Biotechnology,
Inc.) following separation on 15% polyacrylamide gels. The cDNA
containing sequences corresponding to amino acids 1 to 11 of avian
c-Src at the 5' end and a Myc-His tag at the 3' end of the mouse
Akt1 open reading frame was inserted into the Klenow-blunted
NheI and PmeI sites of pUSEamp (Upstate Biotechnology, Inc.). The eukaryotic expression vector pCDNA3 and that
incorporating transducin cDNA were kind gifts of Alan Wise, Receptor
Systems, GlaxoWellcome Medicines Research Centre, Stevenage, United
Kingdom. Transfections were performed with 2 µg of DNA following
complex formation with LipofectAMINE reagent as specified by the
manufacturer (Life Technologies). The DNA-containing medium was removed
following incubation for 3 h at 37°C, and the cells were
incubated for an additional 24 h in complete medium before being
transferred onto Thermanox coverslips. Gene expression using immunoblot
analysis as described above was determined immediately prior to partial
denudation, approximately 48 h posttransfection, using a
primary-antibody concentration of 1:1,000. An appropriate antibody for
monitoring expression levels of transducin was purchased from NEN Life
Science Products. Expression of the myristylated, constitutively active
Akt1 was determined using anti-c-Myc Tag antibody.
Identification of G
subunits involved.
To determine if
the contrasting effects on cell growth could be a consequence of the
somatostatin receptor isoforms coupling to different G proteins,
immunoprecipitation experiments were performed using G
subunit-selective antibodies following somatostatin-induced labeling
with [35S]GTP
S. For experiments involving
immunoprecipitation of G
s, G
13, and
G
q/11, cell monolayers were pretreated with Bordetella pertussis toxin (100 ng/ml) for 18 h.
Membrane fractions from CHOsst2(a) and
CHOsst2(b) cells were prepared by Dounce homogenization in
ice-cold lysis buffer (50 mM Tris HCl, 5 mM MgCl2, 10 µg
of leupeptin per ml, 1 µg of soybean trypsin inhibitor per ml, 100 µg of saponin per ml, 0.2 mg of bacitracin per ml, 1 mM
4-(2-aminoethyl)benzenesulfonylfluoride [pH 7.5]). Membrane protein
was adjusted to a concentration of 75 µg/50 µl of assay buffer (50 mM NaCl, 10 mM MgCl2, 10 mM HEPES [pH 7.4]) and incubated
for 2 min at 30°C with [35S]GTP
S (2 nM) following a
preincubation (2 min at 30°C) with somatostatin (300 nM). The
reactions were terminated by the addition of 500 µl of ice-cold assay
buffer and subsequent centrifugation at 18,000 × g for
5 min at 4°C. Membrane pellets were vortexed in solubilization buffer
(100 mM Tris HCl, 200 mM NaCl, 1 mM EDTA, 1.25% [vol/vol] Nonidet
P-40, 0.2% [wt/vol] SDS [pH 7.4]) and precleared for 1 h at
4°C with 20 µl of rabbit serum (1:100 final dilution) and then
added as a 20% (vol/vol) protein G-bead suspension in solubilization
buffer (without SDS and supplemented with 2% [wt/vol] bovine serum
albumin and 0.1% [wt/vol] NaN3). The beads were
pelleted, and 100 µl of the supernatant was added to tubes containing
protein G suspension (40 µl) and a 1:200 final dilution of the G
protein antibody, supplied by NEN Life Science Products (polyclonal
EC/2 cross-reacting with G
i3 and G
0 and
polyclonal AS/7 cross-reacting with G
i1 and
G
i2) or Santa Cruz Biotechnology (for G
s
[K-20], G
0 [K-20], G
13 [A-20], and
G
q/11 [C-19]). Samples were gently agitated for 2 to
3 h at 4°C. Washed immunocomplexes were suspended in scintillant
and counted. The results are expressed (arithmetic mean ± standard error of the mean) as the percent stimulation over the basal
level (n = 3). Statistical analysis was by Student's
t test. [35S]GTP
S (specific activity, 1,000 to 1,100 µCi/mmol) and GammaBind G Sepharose beads were from Amersham.
 |
RESULTS |
Proliferative properties of G-protein-coupled receptor
isoforms.
We assessed the ability of various treatments to
modulate the proliferative outcome of both recombinant
sst2(a) [CHOsst2(a)] and sst2(b)
[CHOsst2(b)] receptor-expressing lines by determining the
repopulation of denuded areas in confluent monolayers by directly counting viable cells. Parallel denuded areas were created by dragging
a Perspex comb across cell monolayers grown on coverslips (40). Application of somatostatin (100 nM) immediately
following denudation, in the absence of other exogenously added
mitogenic factors, had no significant effect on the number of viable
CHOsst2(a) cells counted 24 h later compared to the
basal value (Fig. 1A). In contrast,
somatostatin (100 nM) caused a significant increase in
CHOsst2(b) cell numbers (Fig. 1B), which was comparable to that induced by bFGF (Fig. 1B), using a concentration (10 ng/ml) which
produced 80% of its maximal response. The specific inhibitors of MEK1
and p38 kinase, PD 98059 (20 µM) and PD 169316 (10 µM), respectively, had no significant effect on basal proliferation of
CHOsst2(a) cells in either the presence or absence of
somatostatin (Fig. 1A). However, the increase in proliferation elicited
by somatostatin in CHOsst2(b) cells was abolished by PD
98059, while PD 169316 was without effect (Fig. 1B). The PI 3-K
inhibitor, LY 294002 (100 µM), also blocked the sst2(b)
receptor-mediated proliferative response (Fig. 1B) while having no
significant effect on basal proliferation in either the
sst2(a) or sst2(b) receptor-expressing lines
(Fig. 1A and B).

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 1.
Effect of somatostatin on cell proliferation and the
phosphorylation status of MAP kinases and Akt in CHO-K1 cells
recombinantly expressing sst2(a) or sst2(b)
receptors. (A and B) The number of CHOsst2(a) (A) and
CHOsst2(b) (B) cells harvested from a single coverslip
following incubation with 100 nM somatostatin (SRIF; solid histograms)
in the presence or absence of the MEK1 inhibitor PD 98059 (20 µM)
(MEK), the PI 3-K inhibitor LY 294002 (100 µM) (PI), or the p38
inhibitor PD 169316 (10 µM) (p38) 24 h after application to
partially denuded cell monolayers is shown. Open histograms indicate
basal repopulation; hatched histograms indicate the induced increase in
cell number obtained with bFGF (10 ng/ml). Groups labeled with an
asterisk are significantly different from basal (P < 0.001), and those labeled with a pound sign are significantly
different from that incubated in the presence of somatostatin
(P < 0.01). (C and D) Changes induced in the
phosphorylation status of ERK1, ERK2, p38, and Akt during initial
processes in the repopulation of partially denuded monolayers of
CHOsst2(a) (C) or CHOsst2(b) (D) cells, as
determined by Western analysis. Whole-cell extracts were prepared from
confluent monolayers immediately following denudation
(T0) and after incubation with incomplete medium
(Basal) or 100 nM somatostatin for the times shown (in minutes). The
consistency of protein loading was substantiated by determining the
immunoreactivity of samples with phosphorylation state-independent
anti-ERK antibodies. Phosphorylation changes were demonstrated by
detection with an antibody to ERK1 and ERK2 that recognizes only the
doubly phosphorylated (at Thr202 and Tyr204)
and hence active forms. Similarly, p38 activation was assessed using an
antibody specific for the doubly phosphorylated form at residues
Thr180 and Tyr182 within the TGY sequence. The
phosphospecific antibody for Akt recognizes this kinase only when
phosphorylated at Ser473, which was shown to correlate with
Akt activation. Cross-reactivity of the phosphospecific antibodies was
not observed in this study.
|
|
Kinetics of ERK, p38, and Akt phosphorylation.
To correlate
the effects observed on CHOsst2(a) and
CHOsst2(b) cell proliferation with the activation of a
particular kinase cascade, we analyzed whole-cell protein extract by
Western blotting using antibodies specific for the phosphorylated and
hence active forms of MAP kinases and Akt. A time course of the
immunoreactivity detected with the antiphosphospecific antibodies over
the initial 4 h of basal repopulation and that in the presence of
somatostatin (100 nM) is shown in Fig. 1. During this period and
irrespective of drug treatment, there was no detectable change in the
expression of the kinases examined and the immunoreactivity obtained
using phosphorylation state-independent pan antibodies to ERK1 and ERK2 was provided for both recombinant lines (Fig. 1C and D). However, electrophoretic mobility shifts for both ERK1 and ERK2 could be observed in the treatment groups where a marked change in the phosphorylation status of these proteins had occurred. Similar observations were apparent using antibodies to p38, SAPKs, and Akt in
both cell lines.
Before and immediately following partial denudation, phosphorylated
forms of ERK1, ERK2, p38, and Akt were undetectable in
either
recombinant line (Fig.
1C and D). Under basal repopulation
conditions,
a small and transient increase in the phosphorylation
of ERK1 and ERK2
was observed for both CHOsst
2(a) (Fig.
1C) and
CHOsst
2(b) (Fig.
1D) cells, falling to undetectable levels
by
60 min postdenudation. However, no immunoreactivity was detected
in
either cell line using antibodies to the phosphorylated forms
of p38 or
Akt, at any time point investigated during the initial
basal
repopulation processes (Fig.
1C and D). This suggests that
the partial
denudation process, possibly through disruption of
zonular adheren
sites, can selectively trigger some signaling
pathways which may
contribute to basal repopulation. However,
the apparent ineffectiveness
of the MEK1 inhibitor on this process
also suggests that multiple,
parallel pathways are involved in
basal repopulation and that a
blockade of any individual cascade
can be effectively
circumvented.
Application of somatostatin (100 nM) to either CHOsst
2(a)
or CHOsst
2(b) cells immediately after partial denudation
evoked
a marked increase in the phosphorylation of ERK1 and ERK2 with
a
maximal response at 10 min, and although this level subsequently
declined, that observed at 4 h postdenudation was increased over
basal (Fig.
1C and D). At no time point during the initial 4 h
of
repopulation processes could phosphorylated Akt be detected
in
CHOsst
2(a) cells treated with somatostatin (Fig.
1C). In
CHOsst
2(b) cells, however, somatostatin induced a transient
phosphorylation
of Akt, which peaked 20 min following partial
denudation and had
declined to basal levels by approximately 2 h
(Fig.
1D), suggesting
that the onset of this pathway is slower than
that for ERK activation.
Phosphorylation of p38 by somatostatin was
apparent in both recombinant
lines, but temporal differences were
observed between phosphorylation
mediated by the different receptor
types. Activation of sst
2(a) receptors induced a persistent
phosphorylation of p38 (Fig.
1C),
whereas activation of
sst
2(b) receptors caused a transient phosphorylation
that
had declined to undetectable levels by 30 min postdenudation
(Fig.
1D).
At no time point during the initial 4 h of repopulation processes
could phosphorylated forms of the SAPKs be detected in either
cell line
treated under basal conditions or with somatostatin
(100 nM)
(determination following incubation for 10 min is shown
in Fig.
2). Western analysis, however, revealed
CHO-K1 cells to
express both the p54 and p46 forms of the SAPKs (Fig.
2A). Phosphorylation
of these proteins was detected following
application of UTP (100
nM) for 10 min immediately after partial
denudation (Fig.
2B),
although there was no detectable activation of
Akt by UTP at this
time point, in contrast to that mediated by
sst
2(b) receptors,
and the UTP-induced phosphorylation of
p38 was not as marked as
that evoked by sst
2(a) receptors
(Fig.
2B). It is possible that
UTP is acting through endogenous
P2Y
2 receptors that exhibit a
widespread distribution.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 2.
Changes in the phosphorylation status of SAPKs, p38, and
Akt in CHO-K1 cells recombinantly expressing sst2(a) or
sst2(b) receptors. Whole-cell extracts were prepared from
partially denuded confluent monolayers after incubation for 10 min with
incomplete medium (CON), 100 nM somatostatin (SRIF), or 100 nM UTP and
analyzed by Western blotting. (A) The consistency of protein loading
was substantiated by determining the immunoreactivity of samples with
phosphorylation state-independent antibodies to Akt, p38, and the
SAPKs. (B) Phosphorylation changes were demonstrated by detection with
an antibody to p38 and Akt that recognizes only the phosphorylated and
hence active forms. Similarly, SAPK activation was assessed using an
antibody specific for the doubly phosphorylated forms of all SAPK
isoforms at residues Thr183 and Tyr185 within
the TPY sequence.
|
|
Antiproliferative function against bFGF.
In
CHOsst2(a) cells, the proliferative effect induced by bFGF
(10 ng/ml) was abolished on coapplication with somatostatin (100 nM) to
values not significantly different from basal (Fig. 3A) whereas activated sst2(b)
receptors were without effect (data not shown). The increase in cell
number induced by bFGF was partially inhibited by PD 98059 or LY 294002 and unaffected by PD 169316 (Fig. 3A). The sst2(a)
receptor-mediated antiproliferative effect of somatostatin, however,
was blocked by the p38 inhibitor (Fig. 3A).

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of somatostatin on bFGF-induced cell
proliferation in CHOsst2(a) cells and the phosphorylation
changes observed in MAP kinases and Akt following concomitant
activation of bFGF and either sst2(a) or
sst2(b) receptor isoforms. (A) The mean number of
CHOsst2(a) cells harvested from a single partially denuded
coverslip incubated for 24 h with bFGF (10 ng/ml) (hatched
histograms) and the effect of coapplication with 20 µM PD 98059 (MEK), 100 µM LY 294002 (PI), or 10 µM PD 169316 (p38) is shown.
Solid histograms show the effect of 100 nM somatostatin (SRIF) and bFGF
on CHOsst2(a) cell proliferation with or without the kinase
inhibitors present. The group labeled with an asterisk is significantly
different (P < 0.001) from basal (open histogram), and
those labeled with a pound sign are significantly different from
incubation with bFGF (P < 0.01) or with bFGF in the
presence of somatostatin (P < 0.001). (B and C) The
time dependency of ERK1 and ERK2 phosphorylation induced by bFGF and
that evoked by the combined effect of bFGF (10 ng/ml) and somatostatin
(100 nM) in both CHOsst2(a) (B) and CHOsst2(b)
(C) cells. Whole-cell extracts prepared from confluent monolayers
immediately following partial denudation (T0)
and after incubation for the times shown (in minutes) were analyzed by
Western blotting. Detection of phosphorylated ERK1 and ERK2 as well as
Akt and p38 is shown together with the expression levels of ERK1 and
ERK2. (D) An extended time course showing the biphasic activation of
ERK1 and ERK2 following incubation of partially denuded monolayers of
CHO-K1 cells for the times shown (in minutes) with bFGF (10 ng/ml).
|
|
In the presence of bFGF (10 ng/ml), both the CHOsst
2(a) and
CHOsst
2(b) cell lines showed a marked increase in the
phosphorylation
status of ERK1 and ERK2 (Fig.
3B and C). However, in
contrast
to the activation induced by somatostatin treatment, the time
profile of ERK activation by the growth factor appeared biphasic;
a
transient increase occurred between 10 and 20 min with a second
peak
following between 4 and 7 h postdenudation (Fig.
3D). Concomitant
application of somatostatin and bFGF to partially denuded
CHOsst
2(a) (Fig.
3B) or CHOsst
2(b) (Fig.
3C)
cells induced a strong phosphorylation
of ERK1 and ERK2 with similar
kinetics to that obtained in the
presence of somatostatin alone.
Application of bFGF to repopulating
cell monolayers failed to induce an
increase in the phosphorylation
of either p38 or Akt at any time point
investigated (Fig.
3B and
C). The induced phosphorylation of Akt by
somatostatin in CHOsst
2(b) cells was unaffected by the
presence of bFGF in terms of both
the duration of the detected
immunoreactivity (Fig.
3C) and its
intensity (Fig.
4). Application of somatostatin and bFGF
to CHOsst
2(a) cells could not induce the phosphorylation of
Akt (Fig.
3B), although
the phosphorylation of p38 by somatostatin
alone appeared to be
elevated above basal levels for longer in the
presence of the
growth factor (Fig.
3B).

View larger version (70K):
[in this window]
[in a new window]
|
FIG. 4.
Comparison of the changes induced by somatostatin and
bFGF in the phosphorylation status of ERK1, ERK2, p38, and Akt during
initial processes in the repopulation of partially denuded monolayers
of CHOsst2(a) (A) or CHOsst2(b) (B) cells.
Analysis at 10, 60, and 240 min following partial denudation of
confluent monolayers was determined by Western detection with
antibodies specific to Akt, ERK1, ERK2, and p38 or those recognizing
the phosphorylated and thus active forms. The immunoreactivity obtained
with phosphoindependent antibodies shows that expression of the kinases
remained unaffected by the various treatments or between the time
points examined. Whole-cell protein extracts were prepared from
partially denuded monolayers incubated in the presence of incomplete
medium (CON), 100 nM somatostatin (SRIF), 10 ng of bFGF per ml (FGF),
or somatostatin in the presence of bFGF (S+F).
|
|
This latter observation was confirmed by analyzing samples from the
various treatment groups on the same immunoblot (Fig.
4). The detection
with phosphorylation state-independent antibodies
to Akt, ERK1, ERK2,
and p38 shows that the expression of these
kinases was unaffected by
the various treatments and unchanged
over the time course analyzed
(Fig.
4). The intensity of the immunoreactivity
detected with the
anti-phospho-p38 antibody was greater at all
time points examined
during the initial 4 h of repopulation processes
in the presence
of somatostatin with bFGF than for CHOsst
2(a) cells treated
with somatostatin alone (Fig.
4A). This enhancement
of the
phosphorylation of p38 by the addition of bFGF to somatostatin-treated
samples was also evident for CHOsst
2(b) cells (Fig.
4B).
However,
in marked contrast to the prolonged activation by
sst
2(a) receptors,
the phosphorylation of p38 induced by
somatostatin in CHOsst
2(b) cells, irrespective of the
presence of bFGF, was transient (Fig.
4B). Figure
4 also demonstrates
that for both cell lines, the
level of phosphorylated ERK1 and ERK2
induced by somatostatin
in the presence of bFGF was greater than that
for either drug
alone at all time points
examined.
Requirement of prolonged p38 activity for ATF-2 activation.
To
correlate the p38 dependency of the sst2(a)
receptor-mediated antiproliferative effect with the observed
time-related immunoreactivity changes induced by somatostatin in
CHOsst2(a) and CHOsst2(b) cells, we examined
the effect of PD 169316 on the phosphorylation status of activating
transcription factor 2 (ATF-2), a known substrate for p38 kinase.
Activation of this transcription factor requires dual phosphorylation
at threonine 69 and threonine 71, enabling subsequent binding to both
AP-1 and CRE DNA response elements (16). Although both SAPK
and p38 MAP kinases phosphorylate ATF-2 at these sites, we can rule out
any contribution from SAPKs in this study, since no observable change
in the phosphorylation status of SAPKs could be detected under basal
conditions or following somatostatin and bFGF treatments at any time
point investigated throughout the initial 4 h of repopulation
processes for either cell line (Fig. 2).
The time points investigated were chosen to represent both the
transient (10 min) and sustained (120 min) phases of the kinase
activity profiles. The p38 inhibitor had no effect on the
phosphorylation
of ERK1 or ERK2 (Fig.
5A)
or of p38 (data not shown) induced by
somatostatin (100 nM) in
CHOsst
2(a) cells in either the presence
or absence of bFGF
(10 ng/ml), 10 min following partial denudation.
In contrast, ERK
phosphorylation induced by somatostatin at 120
min was enhanced by the
application of the p38 inhibitor, suggesting
that cross talk between
the p38 and ERK cascades exists (Fig.
5A). ATF-2 phosphorylation could
not be detected under basal conditions
or in the presence of bFGF at
either time point examined (Fig.
5A). However, ATF-2 phosphorylation
was evoked by somatostatin
during the sustained phase of p38 activation
and was abolished
by PD 169316 (Fig.
5A). The phospho-ATF-2
immunoreactivity obtained
with somatostatin was also amplified by the
presence of bFGF (Fig.
5A), consistent with the enhanced
phosphorylation of p38 in the
presence of the growth factor. In
contrast, ATF-2 phosphorylation
could not be detected at either time
point by somatostatin treatment
in CHOsst
2(b) cells (data
not shown) and would be in accord with
the sst
2(b) receptor
exhibiting only transient activation of p38.

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 5.
Effect of p38 inhibition on the phosphorylation of
ATF-2, p70rsk, ERK1, and ERK2 and the induction
of p21cip1 following somatostatin and bFGF
application to CHOsst2(a) cells. (A) The effect of 10 µM
PD 169316 (p38) on the phosphorylation of ATF-2,
p70rsk, ERK1, and ERK2 induced by 10 ng of bFGF
per ml (FGF), 100 nM somatostatin (SRIF), or somatostatin in the
presence of bFGF (S+F) at both 10 and 120 min following partial
denudation of confluent monolayers of CHOsst2(a) cells is
shown. Control samples incubated in incomplete medium (CON), with or
without the p38 inhibitor at both time points are also shown. Detection
was made by Western analysis using phosphospecific antibodies.
Transcriptionally active ATF-2 requires phosphorylation of both
Thr69 and Thr71, and the antibody used
recognizes only this doubly phosphorylated form. The activity of
p70rsk is controlled by multiple phosphorylation
events. Ser411, Thr421, and Ser424
lie within a Ser-Pro-rich region located in the pseudosubstrate domain,
and the antibody used detects the kinase when either Thr421
or Ser424 is phosphorylated. (B) Induction of the cell
cycle inhibitor p21cip1 following activation of
either sst2(a) (top panel) or sst2(b) (bottom
panel) receptors. Immediately postdenudation, cell monolayers were
incubated in the presence of incomplete medium (CON), 100 nM
somatostatin (SRIF), 10 ng of bFGF per ml (FGF), or somatostatin and
bFGF (S+F) with and without 20 µM PD 98059 (MEK1) or 10 µM PD
169316 (p38). Whole-cell protein extracts were prepared 24 h later
and analyzed by an anti-p21cip1 antibody
following separation on 15% polyacrylamide gels. For comparison, the
last two lanes of each panel (underscored with dotted line) show the
immunoreactivity obtained from the alternative cell line (i.e., the top
panel shows samples from CHOsst2(b) cells and the bottom
panel shows samples from CHOsst2(a) cells). Western
detection was also performed with an anti- -actin antibody to
demonstrate consistency of protein loading (data not shown).
|
|
Requirement of p38 for p21cip1
induction.
There is accumulating evidence (41, 52)
suggesting that high-intensity Ras stimulation in a number of cell
types can evoke prolonged ERK activation leading to the induction of
the cell cycle inhibitor p21cip1. Data provided
in this study would also suggest that a strong and sustained activation
of ERK1 and ERK2, as observed in both CHOsst2(a) and
CHOsst2(b) cells, cannot alone be responsible for the
induction of such an effective antiproliferative activity. In addition,
ERK phosphorylation was shown to be amplified in the presence of bFGF
following activation of either receptor isoform (Fig. 4), and an
intense ERK activity in CHOsst2(a) cells resulted following
inhibition of p38 (Fig. 5A), despite the ability of this agent to
abolish the antiproliferative effect of somatostatin. We thus
investigated the involvement of p38 in the induction of p21cip1. In CHOsst2(a) cells,
p21cip1 protein expression was elevated over
basal levels following treatment for 24 h with somatostatin (100 nM) in the presence of bFGF (10 ng/ml) (Fig. 5B), whereas in
CHOsst2(b) cells no change was observed in the
immunoreactivity detected with the p21cip1
antibody in the equivalent treatment group (Fig. 5B). The increased expression of p21cip1 was reduced in
CHOsst2(a) cells by the MEK1 inhibitor (Fig. 5B). However,
the p38 inhibitor not only abolished p21cip1
protein expression induced by somatostatin with bFGF but also reduced
basal levels (Fig. 5B). There was no effect on
p21cip1 protein expression levels in
CHOsst2(a) or CHOsst2(b) cell lines by the
application of somatostatin or bFGF alone in either the presence or
absence of PD 98059 or PD 169316 (Fig. 5B).
Requirement of PI 3-K for proliferative activity.
The most
obvious differential transduction event between activated
sst2(a) and sst2(b) receptors, which might
explain their distinct proliferative functions in the absence of
exogenously added mitogenic agents, is the phosphorylation of Akt,
which, together with a concomitant ERK activity, may promote cell cycle progression in sst2(b) receptor-expressing cells. The
somatostatin (100 nM)-induced transient phosphorylation of both Akt and
p70rsk was markedly attenuated by the presence
of the PI 3-K inhibitor and unaffected by PD 98059 or PD 169316 (Fig.
6A). However, the PI 3-K inhibitor had no
effect on the transient or sustained phases of ERK phosphorylation
mediated by sst2(b) receptors (Fig. 6A). In contrast, PD
98059 abolished the sustained ERK phosphorylation and partially
inhibited the transient phase (Fig. 6A). The sst2(a) receptor had no effect on the phosphorylation of
p70rsk (Fig. 5A), in keeping with its lack of
effect on Akt.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 6.
Effect of protein kinase inhibitors on the
somatostatin-induced phosphorylation of p70rsk,
Akt, ERK1, and ERK2 in CHOsst2(b) cells and the ability of
constitutively active Akt to evoke a proliferative activity in
CHOsst2(a) cells. (A) The effect of coincubation for 10 and
120 min with 20 µM PD 98059 (MEK1), 100 µM LY 294002 (PI 3-K), or
10 µM PD 169316 (p38) on the phosphorylation of
p70rsk, Akt, ERK1, and ERK2 induced by 100 nM
somatostatin (SRIF) in partially denuded CHOsst2(b) cell
monolayers. The effect of the inhibitors in the presence of incomplete
medium (CON) is also shown. Detection was performed by Western analysis
using phosphospecific antibodies. (B) Effect of transient expression of
tagged Akt1 with c-src-derived residues required for
myristylation on the number of cells determined 24 h following
application of 100 nM somatostatin (SRIF; solid histograms) in the
absence or presence of 10 µM PD 169316 (PD; shaded histograms) to
partially denuded CHOsst2(a) monolayers. The cell counts
obtained following incubation in the presence of incomplete media
(Basal; open histograms) and with PD 169316 present (PD; hatched
histograms) are shown, and the effect of transfection with the empty
plasmid is represented by the histograms labeled Mock. Values are
expressed as the mean cell number harvested from a single coverslip
(from separate transfections, four replicates). The group labeled with
an asterisk is significantly different from that of mock-transfected
cells (P < 0.01).
|
|
To demonstrate the importance of Akt as opposed to other substrates of
PI 3-K in mediating the proliferative function of the
sst
2(b) receptor type, we transfected
CHOsst
2(a) cells with a
constitutively active mutant of
Akt. There was no significant
difference between basal cell counts
determined 24 h following
partial denudation of confluent
CHOsst
2(a) cells transfected with
either pUSEamp or pUSEamp
containing cDNA for tagged Akt1 with
c-
src-derived residues
required for myristylation (Fig.
6B). Application
of somatostatin (100 nM) had no significant effect compared to
the basal level on the
repopulation of mock-transfected cells
or those expressing active Akt
(Fig.
6B). However, somatostatin
in the presence of the p38 inhibitor
PD 169316 increased cell
counts compared to those obtained with either
drug alone for CHOsst
2(a) cells expressing active Akt but
not for mock-transfected cells
(Fig.
6B). PD 169316 on its own was
without effect (Fig.
6B).
Identification of the G
protein mediating the
effects of sst2(a) and sst2(b) receptors.
To explain the differential abilities of the somatostatin receptor
isoforms to stimulate the PI 3-K and p38 pathways, we examined whether
the sst2(a) or sst2(b) receptors exhibited
preferential coupling to distinct G
protein pools. This was
attempted using an immunoprecipitation strategy following
somatostatin-stimulated labeling of the coupled subunits with
[35S]GTP
S. In the presence of 1 µM GDP, somatostatin
(300 nM) increased total [35S]GTP
S (0.2 nM) binding to
CHOsst2(a) membranes by 644% ± 24% over basal
(pEC50 [the negative logarithm of EC50],
8.9 ± 0.1) and increased binding to CHOsst2(b)
membranes by 501% ± 17% (pEC50, 8.7 ± 0.1)
(n = 5 for both data sets). Optimal agonist-stimulated [35S]GTP
S binding following immunoprecipitation with
G
i1/2, G
i3, or G
0
antibodies could be resolved in the presence of 100 µM GDP. Binding
and immunoprecipitation with antibodies specific for G
s,
G
q/11, or G
13 was performed in the
presence of 1 µM GDP using membranes prepared from pertussis
toxin-treated cells (100 ng/ml for 18 h).
There was no significant difference in the level of somatostatin (300 nM)-induced labeling between G-protein

subunits immunoprecipitated
from either CHOsst
2(a) and CHOsst
2(b) cells,
and the activated
receptor isoforms showed the same preference of
coupling, G
i3 > G
i2 >>
G
0 (Fig.
7A). It should be
noted that CHO-K1 cells
do not express G
i1. In addition,
both the antiproliferative and
proliferative effects of the
sst
2(a) and sst
2(b) receptor types,
respectively (24 h following application of 100 nM somatostatin
to
partially denuded monolayers), were abolished by pertussis
toxin
pretreatment (100 ng/ml, 18 h), whereas the proliferative
activity
induced by bFGF (10 ng/ml) in either cell line was unaffected
(Fig.
7B). Phosphorylation of ERK1, ERK2, p38, and Akt by somatostatin
(100 nM for 10 min) at the appropriate receptor type was also
blocked in
cells pretreated with pertussis toxin, whereas the
level of ERK1 and
ERK2 phosphorylation mediated by bFGF was unaffected
(Fig.
7C).

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 7.
Involvement of G-protein subunits in the mediation
of the proliferative and phosphorylation effects induced by
somatostatin in CHOsst2(a) and CHOsst2(b)
cells. (A) Membrane preparations from either sst2(a) (open
histograms) or sst2(b) (solid histograms)
receptor-expressing cells were preincubated (2 min at 30°C) in the
presence or absence of 300 nM somatostatin and then incubated with 2 nM
[35S]GTP S (2 min at 30°C). Subsequent
immunoprecipitation of G-protein subunits was performed using the
polyclonal antibodies EC/2 (specific for G i3), AS/7
(cross-reacting with G i1 and G i2), K-20
(for G s), K-20 (for G 0), A-20 (for
G 13), and C-19 (for G q/11). Results are
expressed as the percent stimulation over basal values, shown as cpm
under each histogram. G i1 could not be detected by
Western analysis in CHO-K1 cells. Groups labeled with an asterisk
(P < 0.001) or with a pound sign (P < 0.05) are significantly different from basal values (n = 3 or 4). (B) The effect of pertussis toxin pretreatment (100 ng/ml for 18 h) on cell proliferation induced by 100 nM
somatostatin (SRIF; solid histograms), 10 ng of bFGF per ml (hatched
histograms), or somatostatin in the presence of bFGF (S+F; shaded
histograms), determined 24 h following application to partially
denuded monolayers of either CHOsst2(a) (left) or
CHOsst2(b) (right) cells. Basal proliferation in the
presence of incomplete medium is shown by the open histograms. Values
are expressed as the mean cell number harvested from a single coverslip
(n = 3, three replicates). Groups labeled with an
asterisk are significantly different from the respective treatment
group for cells not pretreated with pertussis toxin (P < 0.001). (C) The effect of pertussis toxin pretreatment (100 ng/ml
for 18 h) on the phosphorylation of Akt, ERK1, ERK2, and p38 in
CHOsst2(a) and CHOsst2(b) cells. Western
detection was performed using phosphospecific antibodies of samples
prepared from whole-cell extracts of partially denuded monolayers
incubated for 10 min in the presence of incomplete medium (CON), 100 nM
somatostatin (SRIF), or 10 ng of bFGF per ml (FGF). Samples from cells
that had been previously incubated with the toxin are underscored.
|
|
Requirement of 
subunits.
The proliferative effect of
the sst2(b) receptor and the antiproliferative effect
of the sst2(a) splice variant were both inhibited by
overexpression of transducin (Fig. 8A),
whereas the proliferative activity induced by bFGF (10 ng/ml) in
either cell line was unaffected. Akt-induced phosphorylation in
CHOsst2(b) cells and the somatostatin-stimulated (100 nM)
phosphorylation of ERK in both recombinant lines was diminished
following transducin overexpression (Fig. 8B). The induced
phosphorylation of p38 mediated by sst2(a) receptors was
also reduced by the expression of the 
sequestrant (Fig. 8B).
However, phosphorylation of ERK1 and ERK2 induced by both bFGF (10 ng/ml) or UPT (100 nM) 10 min following application to partially
denuded monolayers was unaffected by transducin overexpression (Fig.
8C).

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 8.
Involvement of  subunits in the mediation of the
proliferative and phosphorylation effects induced by somatostatin in
CHOsst2(a) and CHOsst2(b) cells. (A) The effect
of transient expression of the  sequestrant transducin on cell
proliferation induced by 100 nM somatostatin (SRIF; solid histograms),
10 ng of bFGF per ml (hatched histograms), or somatostatin in the
presence of bFGF (S+F; shaded histograms), determined 24 h
following application to partially denuded monolayers of either
CHOsst2(a) (left graph) or CHOsst2(b) (right
graph) cells is shown. The effect of transfection with the empty
plasmid, pCDNA3, is represented by the histograms labeled Mock, and
open histograms show basal repopulation. Values are expressed as the
mean cell number harvested from a single coverslip (from two separate
transfections, three replicates). Groups labeled with an asterisk are
significantly different from the respective treatment group for cells
without transducin expression (P < 0.05). Cell samples
extracted immediately prior to partial denudation that had been
transfected 48 h previously with either pCDNA3 (Mock) or pCDNA3
incorporating transducin cDNA (Trans) were analyzed by Western
detection using an appropriate antibody to confirm expression of
transducin (inset). (B) The effect of  sequestration on
somatostatin-induced phosphorylation of ERK1, ERK2, and p38 in
CHOsst2(a) cells or of ERK1, ERK2, and Akt in
CHOsst2(b) cells. Western detection was performed using
phosphospecific antibodies of samples prepared from whole-cell extracts
of partially denuded monolayers incubated in the presence of 100 nM
somatostatin for 10 min. Samples from cells transfected with the empty
plasmid 48 h prior to partial denudation are labeled Mock, and
those from cells expressing transducin are labeled Trans. (C) The
effect of  sequestration on the phosphorylation of ERK1 and ERK2
stimulated by 10 ng of bFGF per ml in CHOsst2(a) cells or
by 100 nM UTP in CHOsst2(b) cells following incubation for
10 min immediately after partial denudation of confluent monolayers.
Western detection was performed using phosphospecific anti-ERK
antibodies of samples prepared from whole cells that had been either
transfected with the empty plasmid 48 h prior to partial
denudation (Mock) or transfected to overexpress transducin (Trans).
|
|
 |
DISCUSSION |
Upon ligand stimulation, G-protein-coupled receptors transduce
their effects through both the GTP-bound G
and the dissociated G
component of the heterotrimeric G protein, directly regulating downstream effectors (33) including adenylate cyclases,
phospholipase C isoforms, ion channels, PI 3-K (42), and Tec
family tyrosine kinases (25). Several G-protein-coupled
receptors, including the somatostatin sst1 (15)
and sst4 (39) receptor types, stimulate the ERK
pathway through a variety of G-protein subunits (17). For
m1 muscarinic acetylcholine and
1-adrenergic
receptors, the activation of ERK is mediated by G
q/11.
In contrast, Gi-coupled m2 muscarinic
acetylcholine,
2-adrenergic and somatostatin
sst4 receptors, and the Gs-coupled
-adrenergic receptor all induce ERK activation through G
. In
this report, we demonstrate that both sst2 splice variants
similarly stimulate ERK through 
release from a pertussis
toxin-sensitive G protein.
Many studies suggest that a signal transduction pathway from G
to
ERK starts at the direct activation of PI 3-K
(26), which
increases the activities of Src family tyrosine kinases (13,
50), in turn leading to tyrosine phosphorylation of Shc (28). Subsequent recruitment of the Grb2-Sos complex to
plasma membranes promotes the exchange of GDP with GTP on Ras and
activates a sequential kinase cascade that includes Raf, MAP kinase
kinase (MEK), and ERK. Data from this study suggest that the
sst2(a) and sst2(b) isoforms have differential
abilities to activate PI 3-K, in that Akt and
p70rsk phosphorylation was observed following
sst2(b) but not sst2(a) receptor stimulation.
However, it should be noted that bFGF also failed to phosphorylate Akt,
although its proliferative function was partially dependent on a PI 3-K
activity. This suggests that the PI 3-K required for bFGF-induced
proliferation, in contrast to that for sst2(b) receptors,
is not able to stimulate the phosphoinositide-dependent kinase present
in CHO-K1 cells and required for Akt activation (1). The
growth factor-stimulated PI 3-K
and the G-protein-coupled receptor-activated PI 3-K
forms (42) both have protein
kinase activity in addition to their lipid kinase function, and it is possible that distinct signals may be generated through differential activation of their intrinsic kinase domains.
The observed blockade of ERK and PI 3-K by the respective inhibitors in
CHOsst2(b) cells is consistent with the dependency of the
proliferative function mediated by this receptor type on both these
effector activities. However, the lack of effect of LY 294002 on the
somatostatin-induced ERK phosphorylation and the ineffectiveness of PD
98059 on Akt and p70rsk activation suggest that
these kinase cascades activated by the sst2(b) receptor are
parallel but distinct. This is in contrast to the cross talk that has
been demonstrated between the ERK and PI 3-K pathways for other
G-protein-coupled receptors (39, 43). Although, ERK and PI
3-K activities are critical for somatostatin to induce a proliferative
function in CHOsst2(b) cells, it appears that a cooperative
effect from both cascades is required since the abolition of either
prevents an increase in cell number. The partial dependency on both PI
3-K and ERK activities for the growth factor-induced proliferative
response, in contrast to that mediated by sst2(b)
receptors, is consistent with the ability of the bFGF receptor to
recruit a multitude of secondary effectors and initiate a number of
distinct yet parallel signaling pathways with noncooperative functional responses.
The proliferative effect of both the sst2(b) and bFGF
receptors was unaffected following inhibition of p38 MAP kinase. In addition, the sst2(b) receptor induced only a transient
activation of p38 and the growth factor receptor had no effect on the
activity status of either the SAPKs or p38. There are very few reports demonstrating an activation of p38 through bFGF receptors. Its activation has been implicated in bFGF-mediated tube formation by
endothelial cells (44) and in bFGF-induced interleukin-6 synthesis in osteoblasts (22) but not in the mechanism
controlling neurite outgrowth (36). A transient activation
of p38 by bFGF has been shown to occur in PC12 cells, whereas a
stronger and more sustained activation has been observed in fibroblasts
(30). Here we show that the sst2(a) receptor can
induce a marked and sustained phosphorylation of p38, and its
antiproliferative function against bFGF-induced growth was critically
dependent on this kinase activity. Both the antiproliferative effect
and the induced p38 phosphorylation were mediated through G
release, consistent with the demonstration that G
can stimulate
p38 activity in HEK293 cells (54) and JNK activity in COS-7
cells (7, 27). The inability of sst2(a)
receptors to mediate a proliferative effect in the presence of the p38
inhibitor despite the induced high-intensity ERK stimulation suggests
that Akt activation is essential for somatostatin-induced
proliferation. This was supported by the demonstration that transient
expression of constitutively active Akt in sst2(a)
receptor-expressing cells enabled a proliferative function to be
detected in response to somatostatin, providing that the p38 cascade
was blocked.
An interesting observation from this study was the enhanced
phosphorylation of both ERK and p38 MAP kinase by the concomitant effect of somatostatin and the growth factor. Since bFGF and
sst2 receptors have the capacity to stimulate ERK1 and
ERK2, the amplification of this signal as observed in the presence of
both ligands was perhaps expected. However, the mechanism by which bFGF
increases the intensity of somatostatin-induced p38 phosphorylation is
unclear. It is possible that bFGF may inhibit members of the
dual-specificity phosphatase family which reverse MAP kinase
activities, enabling high-intensity signals to be observed for
both p38 and ERK in the presence of somatostatin. However, despite the
amplification of somatostatin-induced p38 by bFGF in
CHOsst2(b) cells, the time profile of its activity status
remained transient (>30 min), in marked contrast to the sustained p38
activity induced by sst2(a) receptors (<4 h). An
enhancement of the prolonged phosphorylation of ERK induced by
somatostatin through the sst2(a) receptor was also observed
by inhibiting p38, suggesting that cross talk between the p38 and ERK
cascades exists. Taken together, these data demonstrate that a complex
interplay exists not only between the transduction cascades activated
by a single receptor type but also between those activated by distinct
receptors types.
Further examples of the influence of stimulating two receptor types on
the net activity of a particular signaling pathway were also
demonstrated in this study for the induction of the cell cycle
inhibitor p21cip1 and the level of activation of
the transcription factor ATF-2. The increased expression of
p21cip1 required a sustained activation of both
p38 and ERK with a critical signal strength that was provided in this
system by the cooperative effects of both the growth factor and
sst2(a) receptor activities. The importance of a sustained
p38 activity in mediating the induction of
p21cip1 was further supported by the lack of
effect on the expression of this protein by activated
sst2(b) receptors in the presence of bFGF. This
transduction network combination evoked only transient activation of
p38, although a sustained ERK activity was observed, and the inclusion
of the PI 3-K inhibitor to prevent any involvement by this kinase also
failed to induce p21cip1 (data not shown). This
is the first report of p38 MAP kinase being involved in the induction
of this cell cycle inhibitor, and it is possible that the
antiproliferative function of sst2(a) receptors is mediated
through this pathway. However, in addition to the sustained activity of
p38, ERK is necessary for the increased expression of
p21cip1.
Although this study highlights a correlation between the induction of
p21cip1 and the activity status of ATF-2, we
have not demonstrated a direct involvement of this transcription factor
in the regulation of the cell cycle inhibitor protein. However, it was
apparent, as shown for the induction of p21cip1,
that a prolonged activation of p38 was also required to phosphorylate ATF-2, since this transcription factor was not stimulated by either sst2(b) or bFGF receptors. An increase in the activity of
ATF-2 was observed only during the sustained phase of p38
phosphorylation and was abolished on application of the p38 inhibitor.
The activity of ATF-2 was also amplified by the presence of bFGF,
consistent with the increased stimulation of p38 by the combined
effects of the sst2(a) and growth factor receptors. These
data suggest that varying the duration of the p38 stimulus can induce
differential transcription factor activation. Phosphorylation of ATF-2
and inhibition of the growth factor-induced proliferative response by
somatostatin are both critically dependent on p38 activity, suggesting
that the prolonged p38 activity mediated by sst2(a) receptors and not sst2(b) receptors can account for their
differential antiproliferative effects.
The contrasting growth responses evoked by the sst2 splice
variants can be correlated with their abilities to differentially activate the p38 or Akt pathways, possibly as a consequence of coupling
to distinct G-protein pools. The effects on cell growth and the induced
changes in the phosphorylation status of ERK1, ERK2, p38, and Akt by
the respective somatostatin receptor types were all abolished following
pertussis toxin pretreatment, suggesting that the receptor isoforms
coupled to Gi proteins. The somatostatin-activated receptor
isoforms also exhibited the same preference of coupling to
Gi
3 over Gi
2
subunits, with no significant coupling to G
s, G
q/11 or G
13. It thus seems unlikely that
different
subunit coupling can account for the diversity of
transductional and functional responses exhibited by these receptor
types. However, since all the distinct effects mediated by the splice
variants were antagonized by overexpression of transducin, it remains
possible that coupling to G
i3 with different 
partners may allow the receptor types to selectively activate
transduction pathways as well as those that are common to both
receptors such as adenylate cyclase inhibition.
Recent reports have suggested a role for chronic ERK activation in
mediating the exit from the cell cycle and cellular differentiation (8, 45), whereas in other cell types it is associated with proliferation (9). Such observations indicate the importance of a sustained or transient activation of this particular transduction pathway, as well as cell phenotype, in determining the functional outcome (32). We show in this study that the duration of the p38 MAP kinase cascade, in addition to that of ERK activation, is also
critical for dictating functional responses. The p38 and ERK cascades
exhibit negative cross talk that may have significant consequences for
regulating cellular processes, and the contribution of other input
signals, such as that from bFGF receptors, can generate large
differences in transcriptional events and subsequent protein expression
(Fig. 9). The induction of
p21cip1, for example, requires a critical signal
strength from the p38 and ERK cascades mediated by the interplay of
bFGF and sst2(a) receptor activation, although it has been
shown that when Rho is active, induction of
p21cip1 by Ras is suppressed (34).
The dependency on p38 for p21cip1 expression
also suggests that p38 activity may play a dual role not only in
mediating apoptotic processes but also as an inhibitor of cell
proliferation. This is analogous to that of ERK activation, which can
promote mitogenesis as well as providing protection against apoptosis
(2). The expression of p21cip1 is
transcriptionally regulated by p53 and its function is critical for
p53-dependent G1 growth arrest (19). The p53
gene is mutated in approximately half of all human cancers
(47), and it is possible that activation of
sst2(a) receptors in certain tumors may not result in the
induction of this potent antiproliferative activity. This could perhaps
explain the poor effects of somatostatin analogues in treating the
growth of some cancer cells in the clinical setting (29).

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 9.
The transduction pathways activated by recombinant
somatostatin sst2(a) or sst2(b) receptor
isoforms and proposed mechanism which determines the proliferative fate
of the host cell. G-protein-coupled receptors and receptor tyrosine
kinases stimulate mitogenesis in part via ERKs, which are members of
the MAP kinase family. It is becoming evident that many of the same
intermediates as those utilized by the receptor tyrosine kinases are
involved in the mechanism of ERK activation by G-protein-coupled
receptors. For example, ERK1 and ERK2 are regulated by
Gi-coupled receptors through a Ras-dependent pathway by
stimulating the recruitment of the guanine nucleotide exchange factor,
SOS, into a plasma membrane-associated signaling complex, where it
activates Ras by catalyzing GTP-for-GDP exchange. This recruitment is
the consequence of receptor-mediated stimulation of tyrosine protein
kinases, which phosphorylate adapter proteins including Shc, followed
by the Grb-2-mediated docking of SOS to the plasma membrane.
Considerable evidence supports the role of the Src family kinases in
the Gi-mediated stimulation of ERK1 and ERK2 through a
mechanism dependent on G release. Activation of the other MAP
kinase pathways, such as p38, also involves a cascade of kinases
downstream from Ras family members such as Rac, but little is known
about the mechanism by which G-protein-coupled receptors activate these
alternative signaling pathways. The proliferative response mediated via
the sst2(b) receptor requires a sustained activation of
ERK1 and ERK2 that is  sensitive. However, the proliferative
effect is additionally dependent on a parallel and distinct PI 3-K
pathway, which is also mediated by  release. Substrates of PI 3-K
such as p70rsk, important for protein synthesis
and cell cycle progression, and Akt, which affords protection against
apoptotic processes, are both phosphorylated by activated
sst2(b) receptors. The sustained activation of ERK mediated
by the sst2(a) receptor, together with a  -dependent
prolonged activation of p38, which activates the transcription factor
ATF-2, is required to inhibit the cell growth induced by bFGF.
Amplification of these MAP kinase cascades by the cooperative effects
of the bFGF and sst2(a) receptors enables the induction of
p21cip1, which interacts with cyclin-dependent
kinases associated with cyclins A, D1, D2, D3, and E to inhibit
cyclin-dependent kinase activity and thus block cell cycle
progression.
|
|
The switch from an antiproliferative to a proliferative activity, as
observed for the sst2(b) receptor, appears to be the consequence of poor coupling to the p38 cascade and the selective activation of PI 3-K (Fig. 9). Since the difference between the sst2 receptor isoforms is restricted to their COOH termini,
it would imply that this region determines the selection of the
appropriate 
pairings necessary for interaction with the distinct
kinase cascades; importantly, these results also demonstrate that even more marked functional outcomes can be derived from the small differences in receptor isoforms than has hitherto been shown (20).
 |
ACKNOWLEDGMENTS |
We express our gratitude to John Scott (Vollum Institute) and
Peter Parker (ICRF) for helpful comments.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Glaxo Institute
of Applied Pharmacology, Department of Pharmacology, University of Cambridge, Tennis Court Rd., Cambridge CB2 1QJ, United Kingdom. Phone:
44 1223 334 177. Fax: 44 1223 334 178. E-mail:
wtem15797{at}glaxowellcome.co.uk.
 |
REFERENCES |
| 1.
|
Alessi, D. R., and P. Cohen.
1998.
Mechanism of activation and function of protein kinase B.
Curr. Opin. Genet. Dev.
8:55-62[CrossRef][Medline].
|
| 2.
|
Berra, E.,
M. M. Municio,
L. Sanz,
S. Frutos,
M. T. Diaz-Meco, and J. Moscat.
1997.
Positioning atypical protein kinase C isoforms in the UV-induced apoptotic signaling cascade.
Mol. Cell. Biol.
17:4346-4354[Abstract].
|
| 3.
|
Brevini, T. A. L.,
R. Bianchi, and M. Motta.
1993.
Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: possible mechanism of action.
J. Clin. Endocrinol. Metab.
77:626-631[Abstract].
|
| 4.
|
Brunet, A.,
A. Bonni,
M. J. Zigmond,
M. Z. Lin,
P. Juo,
L. S. Hu,
M. J. Anderson,
K. C. Arden,
J. Blenis, and M. E. Greenberg.
1999.
Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.
Cell
96:857-868[CrossRef][Medline].
|
| 5.
|
Burgering, B. M., and P. J. Coffer.
1995.
Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction.
Nature
376:599-602[CrossRef][Medline].
|
| 6.
|
Chou, M. M., and J. Blenis.
1996.
The 70 kDa S6 kinase complexes with and is activated by the Rho family G proteins Cdc42 and Rac1.
Cell
85:573-583[CrossRef][Medline].
|
| 7.
|
Coso, O. A.,
H. Teramoto,
W. F. Simonds, and J. S. Gutkind.
1996.
Signaling from G protein-coupled receptors to c-Jun kinase involves  subunits of heterotrimeric G proteins acting on a Ras and Rac1-dependent pathway.
J. Biol. Chem.
271:3963-3966[Abstract/Free Full Text].
|
| 8.
|
Cowley, S.,
H. Paterson,
P. Kemp, and C. J. Marshall.
1994.
Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation.
Cell
77:841-852[CrossRef][Medline].
|
| 9.
|
Cressman, D. E.,
L. E. Greenbaum,
R. A. DeAngelis,
G. Ciliberto,
E. E. Furth,
V. Poli, and R. Taub.
1996.
Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice.
Science
274:1379-1383[Abstract/Free Full Text].
|
| 10.
|
Cuenda, A., and P. Cohen.
1999.
Stress-activated protein kinase-2/p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis.
J. Biol. Chem.
274:4341-4346[Abstract/Free Full Text].
|
| 11.
|
Datta, S. R.,
H. Dudek,
X. Tao,
S. Masters,
H. Fu,
Y. Gotoh, and M. E. Greenberg.
1997.
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.
Cell
91:231-241[CrossRef][Medline].
|
| 12.
|
Dikic, I.,
J. Schlessinger, and I. Lax.
1994.
PC12 cells overexpressing the insulin receptor undergo insulin-dependent neuronal differentiation.
Curr. Biol.
4:702-708[CrossRef][Medline].
|
| 13.
|
Dikic, I.,
G. Tokiwa,
S. Lev,
S. A. Courtneidge, and J. Schlessinger.
1996.
A role for Pyk2 and Src in linking G protein-coupled receptors with MAP kinase activation.
Nature
383:547-550[CrossRef][Medline].
|
| 14.
|
Dudek, H.,
S. R. Datta,
T. F. Franke,
M. J. Birnbaum,
R. Yao,
G. M. Cooper,
R. A. Segal,
D. R. Kaplan, and M. E. Greenberg.
1997.
Regulation of neuronal survival by the serine-threonine protein kinase Akt.
Science
275:661-665[Abstract/Free Full Text].
|
| 15.
|
Florio, T.,
H. Yao,
K. D. Carey,
T. J. Dillon, and P. J. S. Stork.
1999.
Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1).
Mol. Endocrinol.
13:24-37[Abstract/Free Full Text].
|
| 16.
|
Gupta, S.,
D. Campbell,
B. Derijard, and R. J. Davis.
1995.
Transcription factor ATF2 regulation by the JNK signal transduction pathway.
Science
267:389-393[Abstract/Free Full Text].
|
| 17.
|
Gutkind, J. S.
1998.
The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades.
J. Biol. Chem.
273:1839-1842[Free Full Text].
|
| 18.
|
Ip, Y. T., and R. J. Davis.
1998.
Signal transduction by the c-Jun N-terminal kinase (JNK) from inflammation to development.
Curr. Opin. Cell Biol.
10:205-219[CrossRef][Medline].
|
| 19.
|
Kachnic, L. A.,
B. Wu,
H. Wunsch,
K. L. Mekeel,
J. S. DeFrank,
W. Tang, and S. N. Powell.
1999.
The ability of p53 to activate downstream genes p21(WAF1/cip1) and MDM2, and cell cycle arrest following DNA damage is delayed and attenuated in scid cells deficient in the DNA-dependent protein kinase.
J. Biol. Chem.
274:13111-13117[Abstract/Free Full Text].
|
| 20.
|
Kilpatrick, G. J.,
F. M. Dautzenberg,
G. R. Martin, and R. M. Eglen.
1999.
7TM receptors: the splicing on the cake.
Trends Pharmacol. Sci.
20:294-301[CrossRef][Medline].
|
| 21.
|
Klippel, A.,
M. A. Escobedo,
M. S. Wachowicz,
G. Apell,
T. W. Brown,
M. A. Giedlin,
W. M. Kavanaugh, and L. T. Williams.
1998.
Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation.
Mol. Cell. Biol.
18:5699-5711[Abstract/Free Full Text].
|
| 22.
|
Kozawa, O.,
H. Tokuda,
H. Matsuno, and T. Uematsu.
1999.
Involvement of p38 mitogen-activated protein kinase in basic fibroblast growth factor-induced interleukin-6 synthesis in osteoblasts.
J. Biol. Chem.
74:479-485.
|
| 23.
|
Kyriakis, J. M., and J. Avruch.
1996.
Protein kinase cascades activated by stress and inflammatory cytokines.
Bio Essays
18:567-577[CrossRef][Medline].
|
| 24.
|
Kyriakis, J. M., and J. Avruch.
1996.
Sounding the alarm: protein kinase cascades activated by stress and inflammation.
J. Biol. Chem.
271:24313-24316[Free Full Text].
|
| 25.
|
Langhans-Rajasekaran, S. A.,
Y. Wan, and X.-Y. Huang.
1995.
Activation of Tsk and Btk tyrosine kinases by G protein  subunits.
Proc. Natl. Acad. Sci. USA
92:8601-8605[Abstract/Free Full Text].
|
| 26.
|
Lopez-Ilasaca, M.,
P. Crespo,
P. G. Pellici,
J. S. Gutkind, and R. Wetzker.
1997.
Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase .
Science
275:394-397[Abstract/Free Full Text].
|
| 27.
|
Lopez-Ilasaca, M.,
J. S. Gutkind, and R. Wetzker.
1998.
Phosphoinositide 3-kinase is a mediator of the G -dependent Jun kinase activation.
J. Biol. Chem.
273:2505-2508[Abstract/Free Full Text].
|
| 28.
|
Luttrell, L. M.,
G. J. Della Rocca,
T. van Biesen,
D. K. Luttrell, and R. J. Lefkowitz.
1997.
G subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for G protein-coupled receptor-mediated Ras activation.
J. Biol. Chem.
272:4637-4644[Abstract/Free Full Text].
|
| 29.
|
Macaulay, V. M.,
I. E. Smith,
M. J. Everard,
J. D. Teale,
J. C. Reubi, and J. L. Millar.
1991.
Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer.
Br. J. Cancer
64:451-456[Medline].
|
| 30.
|
Maher, P.
1999.
p38 mitogen-activated protein kinase activation is required for fibroblast growth factor-2-stimulated cell proliferation but not differentiation.
J. Biol. Chem.
274:17491-17498[Abstract/Free Full Text].
|
| 31.
|
Marinissen, M. J.,
M. Chiariello,
M. Pallante, and J. S. Gutkind.
1999.
A network of mitogen-activated protein kinases links G protein-coupled receptors to the c-jun promoter: a role for c-Jun NH2-terminal kinase, p38s, and extracellular signal-regulated kinase 5.
Mol. Cell. Biol.
19:4289-4301[Abstract/Free Full Text].
|
| 32.
|
Marshall, C. J.
1995.
Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.
Cell
80:179-185[CrossRef][Medline].
|
| 33.
|
Neer, E. J.
1995.
Heterotrimeric G proteins: organisers of transmembrane signals.
Cell
80:249-257[CrossRef][Medline].
|
| 34.
|
Olson, M. F.,
H. F. Paterson, and C. J. Marshall.
1998.
Signals from Ras and Rho GTPases interact to regulate expression of p21WAF1/Cip1.
Nature
394:295-299[CrossRef][Medline].
|
| 35.
|
Pagliacci, M. C.,
R. Tognellini,
F. Grignani, and I. Nicoletti.
1991.
Inhibition of human breast cancer cell (MCF-7) growth in vitro by the somatostatin analog SMS 201-995: effects on cell cycle parameters and apoptotic cell death.
Endocrinology
129:2555-2562[Abstract/Free Full Text].
|
| 36.
|
Perron, J. C., and J. L. Bixby.
1999.
Distinct neurite outgrowth signaling pathways converge on ERK activation.
Mol. Cell. Neurosci.
13:362-378[CrossRef][Medline].
|
| 37.
|
Price, D. J.,
J. R. Grove,
V. Calvo,
J. Avruch, and B. E. Bierer.
1992.
Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase.
Science
257:973-977[Abstract/Free Full Text].
|
| 38.
|
Schindler, M.,
E. J. Kidd,
A. M. Carruthers,
M. A. Wyatt,
E. M. Jarvie,
L. A. Sellers,
W. Feniuk, and P. P. A. Humphrey.
1998.
Molecular cloning and functional characterisation of a rat somatostatin sst2(b) receptor splice variant.
Br. J. Pharmacol.
125:209-217[CrossRef][Medline].
|
| 39.
|
Sellers, L. A.
1999.
Prolonged activation of extracellular signal-regulated kinase by a protein kinase C-dependent and N17Ras-insensitive mechanism mediates the proliferative response of Gi/0-coupled somatostatin sst4 receptors.
J. Biol. Chem.
274:24280-24288[Abstract/Free Full Text].
|
| 40.
|
Sellers, L. A.,
W. Feniuk,
P. P. A. Humphrey, and H. Lauder.
1999.
Activated G protein-coupled receptor induced tyrosine phosphorylation of STAT3 and agonist-selective serine phosphorylation via sustained stimulation of mitogen-activated protein kinase: resultant effects on cell proliferation.
J. Biol. Chem.
274:16423-16430[Abstract/Free Full Text].
|
| 41.
|
Sewing, A.,
B. Wiseman,
A. C. Lloyd, and H. Land.
1997.
High-intensity Raf signal causes cell cycle arrest mediated by p21cip1.
Mol. Cell. Biol.
17:5588-5597[Abstract].
|
| 42.
|
Stephens, L. R.,
A. Eguinoa,
H. Erdjument-Bromage,
M. Lui,
F. Cooke,
J. Coadwell,
A. S. Smrcka,
M. Thelen,
K. Cadwallader,
P. Tempst, and P. T. Hawkins.
1997.
The G sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101.
Cell
89:105-114[CrossRef][Medline].
|
| 43.
|
Takeda, H.,
T. Matozaki,
T. Takada,
T. Noguchi,
T. Yamao,
M. Tsuda,
F. Ochi,
K. Fukunaga,
K. Inagaki, and M. Kasuga.
1999.
PI 3-kinase and protein kinase C mediate Ras-independent activation of MAP kinase by a Gi protein-coupled receptor.
EMBO J.
18:386-395[CrossRef][Medline].
|
| 44.
|
Tanaka, K.,
M. Abe, and Y. Sato.
1999.
Roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis.
Jpn. J. Cancer Res.
90:647-654[CrossRef][Medline].
|
| 45.
|
Tombes, R. M.,
K. L. Auer,
R. Mikkelsen,
K. Valerie,
M. P. Wymanns,
C. J. Marshall,
M. McMahon, and P. Dent.
1998.
The mitogen-activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic.
Biochem. J.
330:1451-1460.
|
| 46.
|
Traverse, S.,
K. Seedorf,
H. Paterson,
C. J. Marshall,
P. Cohen, and A. Ullrich.
1994.
EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor.
Curr. Biol.
4:694-701[CrossRef][Medline].
|
| 47.
|
Ullrich, S. J.,
K. Sakaguchi,
S. P. Lees-Miller,
M. Fiscella,
W. E. Mercer,
C. W. Anderson, and E. Appella.
1993.
Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumours is altered compared to wild-type p53.
Proc. Natl. Acad. Sci. USA
90:5954-5958[Abstract/Free Full Text].
|
| 48.
|
Vaux, D. L.
1997.
CED-4: the third horseman of apoptosis.
Cell
90:389-390[CrossRef][Medline].
|
| 49.
|
Verheij, M.,
R. Bose,
X. H. Lin,
B. Yao,
W. D. Jarvis,
S. Grant,
M. J. Birrer,
E. Szabo,
L. I. Zon,
J. M. Kyriakis,
A. Haimovitz-Friedman,
Z. Fuks, and R. N. Kolesnick.
1996.
Requirement for ceramide-initiated SAPK/JNK signaling in stress-induced apoptosis.
Nature
380:75-79[CrossRef][Medline].
|
| 50.
|
Wan, Y.,
T. Kurosaki, and X. Y. Huang.
1996.
Tyrosine kinases in activation of the MAP kinase cascade by G protein-coupled receptors.
Nature
380:541-544[CrossRef][Medline].
|
| 51.
|
Widmann, C.,
S. Gibson,
M. B. Jarpe, and G. L. Johnson.
1999.
Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human.
Physiol. Rev.
79:143-180[Abstract/Free Full Text].
|
| 52.
|
Woods, D.,
D. Parry,
H. Cherwinski,
E. Bosch,
E. Lees, and M. McMahon.
1997.
Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21cip1.
Mol. Cell. Biol.
17:5598-5611[Abstract].
|
| 53.
|
Xia, Z.,
M. Dickens,
J. Raingeaud,
R. J. Davis, and M. E. Greenberg.
1995.
Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis.
Science
270:1326-1331[Abstract/Free Full Text].
|
| 54.
|
Yamauchi, J.,
M. Nagao,
Y. Kaziro, and H. Itoh.
1997.
Activation of p38 mitogen-activated protein kinase by signaling through G protein-coupled receptors. Involvement of G and G q/11 subunits.
J. Biol. Chem.
272:27771-27777[Abstract/Free Full Text].
|
| 55.
|
Yang, X.,
R. Khosravi-Far,
H. Y. Chang, and D. Baltimore.
1997.
Daxx, a novel Fas-binding protein that activates JNK and apoptosis.
Cell
89:1067-1076[CrossRef][Medline].
|
| 56.
|
Zanke, B. W.,
K. Boudreau,
E. Reubie,
E. Winnett,
L. A. Tibbles,
L. Zon,
J. Kyriakis,
F. F. Liu, and J. R. Woodgett.
1996.
The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat.
Curr. Biol.
6:606-613[CrossRef][Medline].
|
Molecular and Cellular Biology, August 2000, p. 5974-5985, Vol. 20, No. 16
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Huang, C.-C., You, J.-L., Wu, M.-Y., Hsu, K.-S.
(2004). Rap1-induced p38 Mitogen-activated Protein Kinase Activation Facilitates AMPA Receptor Trafficking via the GDI{middle dot}Rab5 Complex: POTENTIAL ROLE IN (S)-3,5-DIHYDROXYPHENYLGLYCINE-INDUCED LONG TERM DEPRESSION. J. Biol. Chem.
279: 12286-12292
[Abstract]
[Full Text]
-
Lahlou, H., Saint-Laurent, N., Esteve, J.-P., Eychene, A., Pradayrol, L., Pyronnet, S., Susini, C.
(2003). sst2 Somatostatin Receptor Inhibits Cell Proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 Activation. J. Biol. Chem.
278: 39356-39371
[Abstract]
[Full Text]
-
Dumont, J. E., Dremier, S., Pirson, I., Maenhaut, C.
(2002). Cross signaling, cell specificity, and physiology. Am. J. Physiol. Cell Physiol.
283: C2-C28
[Abstract]
[Full Text]
-
Ferreira, C. G., Epping, M., Kruyt, F. A. E., Giaccone, G.
(2002). Apoptosis: Target of Cancer Therapy. Clin. Cancer Res.
8: 2024-2034
[Abstract]
[Full Text]
-
Alderton, F., Humphrey, P. P. A., Sellers, L. A.
(2001). High-Intensity p38 Kinase Activity Is Critical for p21cip1 Induction and the Antiproliferative Function of Gi Protein-Coupled Receptors. Mol. Pharmacol.
59: 1119-1128
[Abstract]
[Full Text]
-
Sellers, L. A., Simon, J., Lundahl, T. S., Cousens, D. J., Humphrey, P. P. A., Barnard, E. A.
(2001). Adenosine Nucleotides Acting at the Human P2Y1 Receptor Stimulate Mitogen-activated Protein Kinases and Induce Apoptosis. J. Biol. Chem.
276: 16379-16390
[Abstract]
[Full Text]